Targeted cancer therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific molecules that are involved in the growth, progression and spread of cancer.
Each personalized gene profile provides information on current FDA-approved treatment options proven effective for the tumor DNA mutations identified.
Sources: cancer.gov and fda.gov
ALK Fusions
Alectinib
Brigatinib
Ceritinib
Crizotinib
Lorlatinib
ATM (prostate cancer)
Olaparib
BRAF
Dabrafenib plus Trametinib
Encorafenib plus Binimetinib
Vemurafenib plus Cobimetinb
BRCA1/BRCA2
Niraparib
Olarparib
Rucaparib
Talazoparib
BARD1 (prostate cancer)
Olarparib
CDK12 (prostate cancer)
Olarparib
CHEK1 (prostate cancer)
Olarparib
CHEK2 (prostate cancer)
Olarparib
EGFR
Afatinib
Dacomitinib
Erlotinib
Gefitinib
Osimertinib
EGFR exon 20
Amivantamab
Mobocertinib
ERBB2 Gene Amplification
Ado-Trastuzumab Emtansine
Lapatinib
Margetuximab
Neratinib
Pertuzumab
Trastuzumab
Trastuzumab Deruxtecan
EZH2
Tazemetostat
FGFR2/FGFR3 Fusions
Erdafitinib
Infigratinib
Pemigatinib
IDH1
Ivosidenib
KIT
Imatinib
Regorafenib
Ripretinib
Sunitinib
KRAS G12C
Sotorasib
MET
Cabozantinib
Capmatinib
Crizotinib
Tepotinib
NF1
Selumetinib
NTRK Fusions
Entrectinib
Larotrectinib
PALB2 (prostate cancer)
Olarparib
PDGFRA
Avapritinib
Imatinib
PIK3CA
Alpelisib
RET Fusions/Mutations
Pralsetinib
Selpercatinib
ROS1 Fusions
Crizotinib
Entrectinib
SMARCB1
Tazemetostat
MSI-H
Immune Checkpoint Inhibitor
PD-L1
Immune Checkpoint Inhibitor